-
Mashup Score: 22
Background: Patients with peripheral artery disease (PAD) are at heightened risk of acute limb ischemia (ALI), a thrombotic event associated with amputation, disability, and mortality. Prior lower ex
Source: CirculationCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2
August 24, 2021—The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the FDA has approved an expanded peripheral artery
Source: Endovascular TodayCategories: Expert Picks, Latest HeadlinesTweet
-
Mashup Score: 15
Background: Patients with peripheral artery disease (PAD) requiring lower extremity revascularization (LER) are at high risk of adverse limb and cardiovascular events. VOYAGER PAD demonstrated that r
Source: CirculationCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0VOYAGER PAD, Revisited with Marc Bonaca, MD, MPH - 3 year(s) ago
The study author joins to highlight new ADA 2021 findings showing rivaroxaban’s benefit for a subpopulation of diabetic patients.
Source: HCPLive®Categories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0VOYAGER PAD Shows Rivaroxaban Reduces First and Total Ischemic Events in Patients With PAD - Endovascular Today - 3 year(s) ago
May 16, 2021—Findings from the VOYAGER PAD trial demonstrated that rivaroxaban, in addition to low-dose aspirin, significantly reduced the occur
Source: Endovascular TodayCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 5
Marc Bonaca, MD, explains the value of new assessments made in the pivotal peripheral artery disease clinical trial.
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet-
Meta-analysis from @CMichaelGibson and colleagues depicts a distinct window of threat—and research opportunity in #ACS event risk. From #ACC21: https://t.co/kaQjpR0PxU
-
-
Mashup Score: 0VOYAGER PAD with Manesh Patel, MD, and Schuyler Jones, MD - 3 year(s) ago
The Duke investigators return to discuss the pivotal study of rivaroxaban in peripheral artery disease.
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 1
Marc Bonaca, MD, explains the value of new assessments made in the pivotal peripheral artery disease clinical trial.
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 8VOYAGER PAD: Rivaroxaban Reduces Total Events Post Lower Extremity Revascularization - American College of Cardiology - 3 year(s) ago
In patients with peripheral artery disease (PAD) who underwent a lower extremity revascularization (LER), rivaroxaban on top of aspirin significantly reduced the total event burden, according to new results of the VOYAGER PAD trial presented May 16 during ACC.21 and simultaneously published in the Journal of the American College of Cardiology. The primary results from VOYAGER PAD,…
Source: American College of CardiologyCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3
Anthony A. Bavry, M.D., M.P.H., FACC
Source: American College of CardiologyCategories: Cardiology News and Journals, Latest HeadlinesTweet
#OriginalResearch from #VOYAGERPAD Low-dose rivaroxaban plus aspirin ⬇️ acute limb ishcemia post-lower extremity revascularization @MarcBonaca @joshuabeckmanmd @DrSoniaAnand1 @cpcresearch #AHAJournals https://t.co/857j9cgt8t https://t.co/4tkVzni5Fd